Table 5.
Antibiotic use for inpatients by indication and ATC classification
| ATC classification level 4 | HAI | CAI | SAP | MP | Unknown | Total | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | n | % | n | % | N | % | |
| Aminoglycosides | 3 | 8.8 | 15 | 44.1 | 0 | 0.0 | 16 | 47.1 | 0 | 0.0 | 34 | 100.0 |
| Beta-lactam combination penicillin | 14 | 17.7 | 61 | 77.2 | 4 | 5.1 | 0 | 0.0 | 0 | 0.0 | 79 | 100.0 |
| Carbapenems | 13 | 100.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 13 | 100.0 |
| Glycopeptides | 3 | 100.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 3 | 100.0 |
| Imidazoles | 11 | 12.1 | 53 | 58.2 | 27 | 29.7 | 0 | 0.0 | 0 | 0.0 | 91 | 100.0 |
| Macrolides | 1 | 5.6 | 16 | 88.9 | 0 | 0.0 | 0 | 0.0 | 1 | 5.6 | 18 | 100.0 |
| Oxazolidinones | 1 | 100.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 100.0 |
| Penicillins (excluding combination penicillins) | 5 | 7.0 | 28 | 39.4 | 22 | 31.0 | 16 | 22.5 | 0 | 0.0 | 71 | 100.0 |
| Fluoroquinolones | 1 | 100.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 100.0 |
| Sulphonamide-trimethoprim combination | 0 | 0.0 | 1 | 5.3 | 0 | 0.0 | 18 | 94.7 | 0 | 0.0 | 19 | 100.0 |
| 3GCs | 22 | 25.6 | 57 | 66.3 | 6 | 7.0 | 0 | 0.0 | 1 | 1.2 | 86 | 100.0 |
| Total | 74 | 17.8 | 231 | 55.5 | 59 | 14.2 | 50 | 12.0 | 2 | 0.5 | 416 | 100.0 |
3GC third-generation cephalosporin, ATC Anatomical Therapeutic Chemical, CAI community-acquired infection, HAI healthcare-acquired infection, MP medical prophylaxis, SAP surgical antibiotic prophylaxis, n frequency, N population